{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:13:12Z","timestamp":1793578392371,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ygyno.2021.02.018","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T05:21:25Z","timestamp":1613884885000},"page":"502-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee"],"prefix":"10.1016","volume":"161","author":[{"given":"Jean-Emmanuel","family":"Kurtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladyslav","family":"Sukhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwa","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind M.","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Berek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"de Paiva Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effi","family":"Yeoshoua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Ho","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Polleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Strojna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Farrelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schwameis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roldano","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Darlington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orgad","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Roxburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Roy","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_8","key":"10.1016\/j.ygyno.2021.02.018_bb0005","doi-asserted-by":"crossref","first-page":"viii30","DOI":"10.1093\/annonc\/mdx449","article-title":"5th Ovarian Cancer Consensus Conference. Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference","volume":"28","author":"Bookman","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.018_bb0010","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual. Life Res."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.018_bb0015","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Brundage MD; CONSORT PRO group. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.018_bb0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2010.09.025","article-title":"A new index of priority symptoms in advanced ovarian cancer","volume":"120","author":"Jensen","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"JNCI J. National Cancer Instit."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.018_bb0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.02.018_bb0035","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.02.018_bb0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jval.2018.07.875","article-title":"Perceptions of response burden associated with completion of patient-reported outcome assessments in oncology","volume":"22","author":"Atkinson","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.018_bb0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jval.2014.10.007","article-title":"Measuring change in quality of life: bias in prospective and retrospective evaluation","volume":"18","author":"Blome","year":"2015","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.ygyno.2021.02.018_bb0050","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/ijgc-2019-000892","article-title":"Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: a NOGGO\/ENGOT-ov22 and GCIG survey (expression IV)","volume":"30","author":"Rohr","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2021.02.018_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2017.03.019","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer","volume":"78","author":"Joly","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"34","key":"10.1016\/j.ygyno.2021.02.018_bb0060","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1200\/JCO.19.00917","article-title":"Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: a TWiST analysis of the ENGOT-OV16\/NOVA trial","volume":"37","author":"Matulonis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0065","first-page":"106(9)","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"29","author":"Basch","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0070","series-title":"The Use of the EORTC Item Library to Supplement EORTC Quality of Life Instruments. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress","author":"Kuli\u015b","year":"2017"},{"issue":"3","key":"10.1016\/j.ygyno.2021.02.018_bb0075","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00432-018-02835-6","article-title":"ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study","volume":"145","author":"Livanainen","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2018.04.016","article-title":"European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire","volume":"100","author":"Petersen","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.02.018_bb0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41687-019-0096-3","article-title":"Do patients consider computer-adaptive measures more appropriate than static questionnaires?","volume":"3","author":"Gamper","year":"2019","journal-title":"J. Patient Rep. Outcomes."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0090","doi-asserted-by":"crossref","first-page":"100399","DOI":"10.1016\/j.conctc.2019.100399","article-title":"Patient preferences for using mobile technologies in clinical trials","volume":"15","author":"Perry","year":"2019","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0095","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(16)00038-3","article-title":"Longitudinal adverse event assessment in oncology clinical trials: the toxicity over time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254","volume":"17","author":"Thanarajasingam","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2021.02.018_bb0100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA."},{"issue":"6","key":"10.1016\/j.ygyno.2021.02.018_bb0105","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/1740774518795637","article-title":"Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials","volume":"15","author":"Bottomley","year":"2018","journal-title":"Clin. Trials."},{"issue":"10","key":"10.1016\/j.ygyno.2021.02.018_bb0110","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2021.02.018_bb0115","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2021.02.018_bb0120","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/sim.1035","article-title":"Combining components of quality of life to increase precision and evaluate trade-offs","volume":"20","author":"Lumley","year":"2001","journal-title":"Stat. Med."},{"issue":"9265","key":"10.1016\/j.ygyno.2021.02.018_bb0125","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(00)04522-0","article-title":"Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours","volume":"357","author":"Shakespeare","year":"2001","journal-title":"Lancet"},{"issue":"5\u20137","key":"10.1016\/j.ygyno.2021.02.018_bb0135","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<725::AID-SIM817>3.0.CO;2-1","article-title":"Practical approaches to minimize problems with missing quality of life data","volume":"17","author":"Simes","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2021.02.018_bb0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1023\/A:1008291825695","article-title":"Improved quality of life with megestrol acetate in patients with endocrine insensitive advanced cancer: a randomised placebo-controlled trial","volume":"8","author":"Beller","year":"1997","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:47:11Z","timestamp":1715820431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0090825821001554"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}